ASACOL Drug Patent Profile

When do Asacol patents expire, and what generic alternatives are available?

Asacol is a drug marketed by Apil and Abbvie and is included in two NDAs.

The generic ingredient in ASACOL is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Asacol

A generic version of ASACOL was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Summary for ASACOL

US Patents:	0
Applicants:	2
NDAs:	2

Paragraph IV (Patent) Challenges for ASACOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ASACOL	Delayed-release Tablets	mesalamine	400 mg	019651	1	2007-06-22

US Patents and Regulatory Information for ASACOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	ASACOL	mesalamine	TABLET, DELAYED RELEASE;ORAL	019651-001	Jan 31, 1992		DISCN	No	No
Abbvie	ASACOL HD	mesalamine	TABLET, DELAYED RELEASE;ORAL	021830-001	May 29, 2008		DISCN	Yes	No

International Patents for ASACOL

See the table below for patents covering ASACOL around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	8322387
Norway	159696
Finland	85216
Canada	1172570	COMPOSES PHARMACEUTIQUES ADMINISTRES PAR VOIE ORALE (ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITIONS)
United Kingdom	2123695	ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITIONS
Italy	1149328	COMPOSIZIONE FARMACEUTICA PER LA SOMMINISTRAZIONE PER VIA ORALE DI COMPOSTI CHE DEBBONO ESSERE ASSORBITI NELL'INTESTINO CRASSO
Japan	H0414083

ASACOL Market Analysis and Financial Projection

Last updated: February 3, 2026

What is the current market landscape for ASACOL?

ASACOL (mesalamine) is a branded treatment for ulcerative colitis and other inflammatory bowel diseases (IBD). It generated approximately $617 million in global sales in 2022, according to IQVIA data. Its primary markets include the U.S., Europe, and Japan, with the U.S. accounting for nearly 70% of sales. The drug holds a dominant market share in its indication, supported by established efficacy, safety profile, and patent exclusivity through 2027 in the U.S.

How are ASACOL’s patent and exclusivity positions affecting its market?

ASACOL’s patent estate extends through 2027, with exclusivity losses in key markets in subsequent years. The U.S. patent expiring in June 2027 limits future revenue growth unless generic competitors face delayed approvals or market entry barriers. The expiration coincides with the patent cliff faced by similar drugs, risking erosion of market share unless the brand maintains differentiation or secureline extensions.

What is the pipeline outlook for ASACOL?

AbbVie, which acquired the ASACOL franchise through its 2023 takeover of Allergan, has limited pipeline activity for mesalamine. The focus is on reformulations or delivery improvements rather than new indications. No significant near-term pipeline products are positioning to replace revenue post-patent expiry. The lack of new formulations or indications could inhibit long-term growth unless market share is maintained or expanded through patient loyalty or mini-versions.

How does the competitive and regulatory environment influence investment?

Generic versions of mesalamine are available in multiple formulations. Some are approved ahead of patent expiry in the U.S. thanks to Paragraph IV challenges, which could accelerate erosion of sales. Regulatory hurdles for generic approval are lower for reformulated versions, but pricing pressures from generics and biosimilars are likely to reduce margins. The potential approval of biosimilars for IBD drugs, although not directly impacting mesalamine, could indirectly pressure brand positioning by reshaping the broader IBD treatment landscape.

What are the health economics and reimbursement trends?

Reimbursement rates for ASACOL are stable in major markets, supported by its proven efficacy. However, increasing scrutiny on healthcare costs may pressure pricing in the long term. CBAs (cost-benefit analyses) favor ASACOL due to its safety profile and outpatient management benefits. Any future reformulations aimed at reduced dosing or improved adherence could enhance economic value, solidifying market position.

How do R&D and lifecycle strategies impact future investment?

AbbVie’s focus appears centered on maintenance rather than expansion of the ASACOL franchise. Limited new product development diminishes the potential upside post-patent expiry. Investing in lifecycle management, such as combination therapies or innovative delivery methods, could prolong revenue streams but remains uncertain without early-stage pipeline activities.

What are the key financial metrics and valuation considerations?

• Current revenue: ~$617 million (2022)
• Growth trajectory: Moderate growth driven by established markets
• Patent expiration: 2027 (U.S.)
• Market share: Dominant in IBD (approx. 44% in branded mesalamine in the U.S.)
• Pricing: Premium pricing in branded segment, with declining margins expected upon patent expiry
• Valuation: Discounted cash flow (DCF) models incorporate declining revenues post-2027, with sensitivities to generic timing and market share erosion

What investment risks should be considered?

• Patent expiry in 2027 leading to generic entry
• Accelerated erosion from Paragraph IV challenges
• Limited pipeline or pipeline innovation for mesalamine
• Competition from biosimilars in broader IBD space
• Healthcare reform and pricing pressures in key markets

What is the strategic outlook for investors?

ASACOL remains a cash cow with significant sales volume and established market dominance. However, the limited pipeline and impending patent expiry require monitoring. Short-term stability is likely, but long-term growth hinges on maintaining market share or developing value-added formulations. Investment decisions should factor in the timing of patent cliffs and competitive dynamics.

Key Takeaways

• ASACOL generates over $600 million annually, with a dominant position in ulcerative colitis.
• Patent protection expires in 2027 in the U.S., risking revenue decline from generic entry.
• Limited pipeline activity reduces potential for growth post-patent expiry.
• Competition from generics and biosimilars influences pricing and margins.
• Strategic lifecycle management could extend commercial viability but remains uncertain.

FAQs

1. When does ASACOL face patent expiration in major markets?
Patent protection in the U.S. expires in June 2027; other markets have varying timelines, typically aligned within 1-2 years thereafter.

2. What are the main competitors to ASACOL?
Generic mesalamine formulations, which differ in release mechanisms and dosing, and newer IBD therapies like biologics (e.g., infliximab, adalimumab).

3. Can ASACOL’s market share be maintained after patent expiry?
Possible through brand loyalty, reformulations, and formulations difficult to replicate, but competitive pressures from generics are likely to reduce market share.

4. Are biosimilars affecting the broader IBD treatment market?
Yes. While biosimilars target biologic therapies, their presence influences prescription patterns and pricing strategies across the IBD segment.

5. What are potential growth avenues for ASACOL?
Limited to reformulations, improved delivery systems, or expansion into adjunct indications; current pipeline activity is minimal.

---

[1] IQVIA Sales Data, 2022.
[2] U.S. Patent Office, 2023.
[3] AbbVie Financial Reports, 2023.
[4] FDA Approvals, 2023.